Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).

ABSTRACT:

Objective

The purpose of this study was to compare effects of insulin detemir once daily versus twice a day in a basal-bolus insulin regimen.

Research design and methods

In this open-label, 7-month study, 520 patients with type 1 diabetes were randomly assigned to receive detemir once daily or twice daily with mealtime insulin aspart. Insulin doses were titrated over 1 month, with patients followed up over the subsequent 3 months. Thereafter, patients were able to switch from one regimen to the other, with an additional nonrandomized 3-month follow-up, to a total of 7 months. The primary end point was A1C at 4 months, with noninferiority defined as a difference <0.4% between groups.

Results

A1C at 4 months was 8.1 +/- 0.9 versus 8.0 +/- 1.0% with once- and twice-daily

SUBMITTER: Le Floch JP 

PROVIDER: S-EPMC2606825 | biostudies-literature | 2009 Jan

REPOSITORIES: biostudies-literature